Funding sources: None.
Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease
Article first published online: 4 APR 2013
© 2013 John Wiley & Sons, Ltd.
Special Issue: Noninvasive Prenatal Testing Using Maternal Plasma DNA: Part I
Volume 33, Issue 6, pages 609–611, June 2013
How to Cite
Osborne, C. M., Hardisty, E., Devers, P., Kaiser-Rogers, K., Hayden, M. A., Goodnight, W. and Vora, N. L. (2013), Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat. Diagn., 33: 609–611. doi: 10.1002/pd.4100
Conflicts of interest: Patricia Devers is an employee of Verinata Health, Inc.
- Issue published online: 17 MAY 2013
- Article first published online: 4 APR 2013
- Manuscript Accepted: 2 MAR 2013
- Manuscript Revised: 28 FEB 2013
- Manuscript Received: 7 FEB 2013
What's already known about this topic?
- Noninvasive prenatal testing for detection of trisomies 21, 18, and 13 is clinically available and is reported to have a false positive rate of 1% or less
- This technology utilizes massively parallel shotgun sequencing of cell-free DNA, of maternal and placental origin, present in maternal plasma
What does this study add?
- Unexplained abnormal noninvasive prenatal testing results should prompt consideration of a maternal source of the abnormal cell-free DNA, such as malignancy